Who are Doxycycline and tauroursodeoxycholic acid's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxycycline-and-tauroursodeoxycholic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Doxycycline and tauroursodeoxycholic acid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doxycycline and tauroursodeoxycholic acid (Doxycycline and tauroursodeoxycholic acid) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (antibiotic + bile acid derivative). Area: Hepatology / Gastroenterology.

phase 3 Combination therapy (antibiotic + bile acid derivative) Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1) Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Doxycycline and tauroursodeoxycholic acid (Doxycycline and tauroursodeoxycholic acid) — Fondazione IRCCS Policlinico San Matteo di Pavia. Doxycycline and tauroursodeoxycholic acid combination works by reducing inflammation and oxidative stress while promoting bile acid signaling to protect mitochondrial function and reduce hepatocellular injury.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxycycline and tauroursodeoxycholic acid TARGET	Doxycycline and tauroursodeoxycholic acid	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Combination therapy (antibiotic + bile acid derivative)	Matrix metalloproteinases, FXR (farnesoid X receptor), TGR5 (G-protein coupled bile acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (antibiotic + bile acid derivative) class)

Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxycycline and tauroursodeoxycholic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/doxycycline-and-tauroursodeoxycholic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab